Twist Bioscience $17,050,000 Settlement, Check If You Qualify Peters v. Twist Bioscience Corp., No. 5:22-cv-08168-EKL

If you bought Twist Bioscience common stock between December 20, 2018, and November 15, 2022 — or picked up shares in the company’s December 2020 stock offering — you’re likely part of Peters v. Twist Bioscience Corp., Case No. 5:22-cv-08168-EKL. Twist agreed to pay $17,050,000 to settle the investor claims against it. You have until November 17, 2026, to file.

Twist Bioscience Securities Settlement — Key Facts

Settlement Amount	$17,050,000.00 (cash)
Claim Deadline	November 17, 2026
Who Qualifies	Investors who purchased or acquired Twist common stock Dec. 20, 2018 – Nov. 15, 2022, or in the Dec. 2, 2020 secondary offering
Estimated Payout	Roughly $0.31 per share on average, before fees and expenses — actual amount varies by purchase price, sale price, and dates
Proof Required (Yes/No)	Yes — broker confirmations, account statements, or other trade documentation
Settlement Status	Preliminarily approved; final approval hearing pending
Court & Case Number	U.S. District Court, N.D. Cal. (San Jose Division), No. 5:22-cv-08168-EKL
Law Alleged	Securities Act §§ 11, 15; Exchange Act §§ 10(b), 20(a)
Administrator	Simpluris, Inc.
Official Claim Site	TwistSecuritiesSettlement.com
Last Updated	September 10, 2026

Who Is Twist Bioscience and Why Are They Being Sued for Securities Fraud?

Twist Bioscience builds synthetic DNA on a proprietary silicon chip, selling genetic material to drugmakers, diagnostics companies, and researchers. Investors bought in expecting that manufacturing edge to translate into cheaper, higher-quality DNA at scale. A November 2022 short-seller report — and the lawsuit that followed — argued Twist’s own numbers didn’t back that story up.

That’s the gap this case is about: what Twist told investors versus what was actually happening inside the business.

What Did Twist Bioscience Do to Investors Between December 2018 and November 2022?

Lead Plaintiff Policemen’s Annuity and Benefit Fund of Chicago says Twist, along with CEO Emily M. Leproust and then-CFO James M. Thorburn, made false and misleading statements about the company’s production process, product quality, and customer satisfaction. The complaint — brought under Sections 11 and 15 of the Securities Act of 1933 and Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 — also claims Twist misstated its research and development expenses, cost of production, and gross margins, accounting choices that made the business look healthier than it was.

Twist hasn’t admitted to any of it. The company and the individual defendants “deny all allegations of fault, liability, wrongdoing, or damages whatsoever,” according to the settlement notice — standard language in a case resolved before trial.

That’s normal legal posture in a settlement like this. But it’s worth knowing before you assume this was ever an open-and-shut case.

Who Qualifies for the Twist Bioscience Securities Settlement?

Here’s exactly how to know if this case includes you.

• Anyone who bought Twist Bioscience common stock (Nasdaq: TWST) on the open market between December 20, 2018, and November 15, 2022
• Investors who acquired shares directly in the December 2, 2020, secondary offering, at $110 per share
• Accounts held through a broker, IRA, trust, or corporation qualify too, as long as the trades happened in that window
• Twist’s own officers, directors, and their immediate family members are excluded from the class
• Anyone who requested exclusion from the class by the October 7, 2026, opt-out deadline is no longer part of it

If you sold your shares before November 15, 2022, you’re still eligible to file — you just won’t recover as much per share as someone who held on through the drop.

Twist Bioscience Investors Outside California — Are You Still Covered?

Yes. This is a federal securities class action, not a state-law case, so where you live doesn’t affect your eligibility. What matters is where and when you bought the stock. Investors anywhere in the U.S. — or abroad, provided the trade was denominated in U.S. dollars — can qualify.

Not sure if you qualify for the Twist Bioscience securities settlement? A free consultation with a securities fraud attorney can help before the November 17, 2026, deadline.

How Much Can Twist Bioscience Settlement Class Members Get? Up to $17,050,000 Total

Plaintiffs’ expert put the average recovery at roughly $0.31 per share, before attorneys’ fees, expenses, and administration costs come out. That number sounds simple. It isn’t — your actual payout depends on when you bought, when you sold, and whether your shares came from the 2020 offering or the open market later.

Twist Bioscience Payout With Proof — Up to $16.37 Per Share (2020 Offering Buyers)

Investors who bought in the December 2020 offering paid $110 a share. If you still held that stock as of the settlement notice date, your recognized loss caps at roughly $16.37 per share under the settlement’s formula. Sell earlier, and a different, smaller formula applies based on your actual sale price.

Twist Bioscience Payout With Proof — Up to $8.11 Per Share (Open-Market Buyers)

If you bought on the open market during the class period, your recovery is tied to how much the stock price was allegedly inflated by the misstatements — capped at $8.11 per share for anyone who sold or held through the 90-day period following the November 2022 disclosure.

What Pro-Rata Means for Your Twist Bioscience Check

The $17,050,000 fund doesn’t pay every claim in full — it pays each valid claim its proportional share of the total “recognized loss” pool. If total claims add up to more than the fund can cover, every check gets scaled down by the same percentage. More filers means smaller checks for everyone.

Lead Counsel is asking the court for up to 25% of the fund — $4,262,500 — plus roughly $850,000 in expenses. Take that off the top, and the real average recovery works out closer to $0.22 per share, not the headline $0.31. That’s normal in a securities case this size. But it’s worth doing that math before you decide the payout is worth your time.

Payments over $600 may appear on a 1099. Check with a tax professional. Claims that calculate to less than $10 won’t be paid at all — that money rolls into everyone else’s checks instead.

How to File Your Twist Bioscience Settlement Claim — Step by Step

1. Go to TwistSecuritiesSettlement.com and open the Proof of Claim and Release form
2. Enter your name, address, and the last four digits of your Social Security or Tax ID number
3. List every purchase, acquisition, and sale of Twist common stock during the class period, in chronological order by trade date
4. Upload your broker confirmations or account statements — the administrator has no independent record of your trades
5. Sign, submit, and save your confirmation
6. Watch your email — Simpluris will acknowledge receipt within 60 days; call 833-386-6546 if you don’t hear back

Takes about 15–20 minutes if you have your brokerage statements on hand. Mark November 17, 2026, on your calendar — that’s the hard deadline, whether you file online or by mail.

Should Twist Bioscience Class Members Opt Out or Object Before November 17, 2026?

What Opting Out of the Twist Bioscience Settlement Actually Means

Opting out means giving up any payment from this settlement — but keeping your right to sue Twist on your own. Most people shouldn’t do this without talking to a lawyer first. The opt-out deadline was October 7, 2026.

How to Object to the Twist Bioscience Settlement

Objecting means staying in the class while telling the court you disagree with some part of the deal — the amount, the attorneys’ fees, or how the money gets divided. Objections must be received (not just postmarked) by the Clerk of the Court, U.S. District Court for the Northern District of California, 280 South 1st Street, Room 2112, San Jose, CA 95113, and must include your name, proof of your trades, and your specific reasons.

Talk to a class action lawsuit attorney before the deadline if you’re considering either option.

Twist Bioscience Securities Settlement — Key Dates, 2026

Milestone	Date
Settlement Reached (Mediation)	March 31, 2026
Preliminary Approval Granted	July 17, 2026
Opt-Out Deadline	October 7, 2026
Objection Deadline	UNVERIFIED — not specified in the Long-Form Notice or Claim Form reviewed
Claim Filing Deadline	November 17, 2026
Final Approval Hearing	November 18, 2026, 10:00 a.m., Courtroom 7, N.D. Cal. (San Jose)
Expected Payment Date	UNVERIFIED — distribution follows final approval and resolution of any appeals; no date posted yet

Twist Bioscience Securities Settlement — Frequently Asked Questions, No. 5:22-cv-08168-EKL

Do I need a lawyer to file a Twist Bioscience settlement claim? 

No. You can file directly at TwistSecuritiesSettlement.com. A securities fraud attorney can help if your trading history is complicated or you’re weighing whether to opt out instead.

Is the Twist Bioscience settlement legitimate? 

Yes. It’s court-supervised. Judge Eumi K. Lee of the Northern District of California granted preliminary approval on July 17, 2026, and a final approval hearing is set for November 18, 2026.

When will Twist Bioscience settlement payments be sent? 

Not yet determined. Payments go out after the court grants final approval and any appeals are resolved — Simpluris hasn’t posted a distribution date.

What if I missed the Twist Bioscience claim deadline?

 Late claims aren’t guaranteed a payout. Contact Simpluris at 833-386-6546 before November 17, 2026, to ask whether a late submission can still be considered.

Do I qualify if I bought Twist stock through my IRA or a brokerage account?

 Yes, as long as the trade happened between December 20, 2018, and November 15, 2022, or in the December 2020 offering. File one claim per legal entity — don’t combine IRA trades with personal ones.

What if I bought and sold Twist stock multiple times during the class period? 

List every transaction separately, in chronological order, on the claim form. The administrator matches your purchases and sales on a first-in, first-out basis to calculate your loss.

Why is the settlement only $17,050,000 when Twist’s stock dropped so much? 

Twist denies wrongdoing, and a trial carried real risk the class could have recovered nothing. Lead Plaintiff’s attorneys weighed that risk against a guaranteed $17.05 million recovery now.

How much could Twist Bioscience investors get if they hold shares from both the 2020 offering and the open market?

 Your claim uses whichever formula produces the greater recognized loss for each purchase — Securities Act or Exchange Act — then adds them together across all your qualifying transactions.

Sources Used in This Twist Bioscience Securities Settlement Article

• Long-Form Notice of Pendency and Proposed Settlement of Class Action, Exhibit A-2, filed April 30, 2026 (ECF No. 166-4): www.TwistSecuritiesSettlement.com
• Proof of Claim and Release Form: TwistSecuritiesSettlement.com/form/securities-claim
• Twist Bioscience Corp. Form 10-Q (period ended June 30, 2026), filed with the SEC: sec.gov
• Bleichmar Fonti & Auld LLP, “Court Grants Preliminary Approval of Settlement in Twist Bioscience Securities Litigation,” July 21, 2026: bfalaw.com
• Bleichmar Fonti & Auld LLP, “BFA Seeks Preliminary Approval of $17.05 Million Settlement of Securities Class Action Against Twist Bioscience Corp.,” May 1, 2026: bfalaw.com

Researched and written by Israr Ahmad, legal content researcher and founder of AllAboutLawyer.com. All facts verified against the official Long-Form Notice, Proof of Claim form, and Twist Bioscience’s SEC filings on September 10, 2026. Last Updated: September 10, 2026.

This article is for informational purposes only and does not constitute legal advice. Laws vary by state and individual circumstances differ. For advice about your specific situation, consult a qualified attorney.